SQUIRE: Reported incidence of dermatologic toxicities1,2

Incidence of dermatologic toxicities chart
Zoom In
Zoom Out
  • Dermatologic toxicities occurred in 79% of patients receiving Portrazza and were severe in 8% of patients1
  • In SQUIRE, preemptive treatment for skin toxicity was allowed only after the first cycle3
  • Skin toxicity usually developed within the first 2 weeks of therapy and resolved within 17 weeks after onset1
  • The most common Portrazza-related toxicity leading to discontinuation was skin rash (1%)1

References: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015. 2. Data on file. Lilly Research Laboratories (ONC20151016a). 3. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774.